Literature DB >> 26827083

Surgical Management of Chronic Wounds.

Benjamin R Johnston1, Austin Y Ha1, Daniel Kwan2.   

Abstract

In this article, we outline the important role the surgeon plays in the management of chronic wounds. Debridement and washout are required for grossly infected wounds and necrotizing soft tissue infections. Cutaneous cancers such as squamous cell carcinomas may contribute to chronic wounds and vice versa; if diagnosed, these should be treated with wide local excision. Arterial, venous, and even lymphatic flows can be restored in select cases to enhance delivery of nutrients and removal of metabolic waste and promote wound healing. In cases where vital structures, such as bones, joints, tendons, and nerves, are exposed, vascularized tissue transfers are often required. These tissue transfers can be local or remote, the latter of which necessitates anastomoses of arteries and veins. Pressure sores are managed by relieving pressure, treating acute trauma or infection, and using rotation fasciocutaneous flaps. Lastly, the surgeon must always consider the possibility of osteomyelitis and retained foreign body as etiology for chronic wounds.

Entities:  

Keywords:  chronic wound,; debridement; flap; pressure sore; surgical management

Mesh:

Year:  2016        PMID: 26827083

Source DB:  PubMed          Journal:  R I Med J (2013)        ISSN: 0363-7913


  2 in total

1.  Pressure Injuries and Management after Spinal Cord Injury.

Authors:  Nicole M Vecin; David R Gater
Journal:  J Pers Med       Date:  2022-07-12

2.  A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  Oryan Henig; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Steve Marshall; Susan D Rudin; T Nicholas Domitrovic; Andrea M Hujer; Kristine M Hujer; Yohei Doi; Scott Evans; Vance G Fowler; Robert A Bonomo; David van Duin; Keith S Kaye
Journal:  Open Forum Infect Dis       Date:  2017-07-27       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.